Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety considerations for normal pediatric hematopoietic cell donors-Reference-Cited by-同舟云学术

Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety considerations for normal pediatric hematopoietic cell donors

Published:2006 Issue:4 Volume:46 Page:422-433
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Pulsipher Michael A.,Nagler Arnon,Iannone Robert,Nelson Robert M.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference81 articles.

1. Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers

2. Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease

3. Comparison of granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood progenitor cells and G-CSF--stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation

4. Impact of stem cell donation modality on normal donor quality of life: a prospective randomized study

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Collection and Transplantation of Peripheral Blood Stem Cells in Children: A Single-Center Experience;Genel Tıp Dergisi;2024-06-30

2. Don de cellules souches hématopoïétiques à partir d’un donneur mineur : cadre réglementaire, information, évaluation de l’aptitude au don et parcours (SFGM-TC);Bulletin du Cancer;2024-05

3. The Philosophical Underpinning of the Family for Pediatric Decision-Making;Pediatric Clinics of North America;2024-02

4. Genotoxicity of cytokines at chemotherapy-induced ‘storm’ concentrations in a model of the human bone marrow;Mutagenesis;2023-06-16

5. Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial;Bone Marrow Transplantation;2022-08-26